Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New glasses could slow Kids' worsening eyesight

NCT ID NCT07008001

Disease control Sponsor: SightGlass Vision, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests special spectacle lenses designed to slow the progression of nearsightedness (myopia) in Chinese children. About 175 children who completed a prior study will wear the lenses for 12 months. Researchers will measure changes in eye length to see if the lenses help control myopia.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Diffusion Optics Technology (DOT) spectacle lenses
What this could lead to
If successful, these lenses could offer a simple, non-invasive way to slow worsening nearsightedness in children, reducing the need for stronger prescriptions.
What could go wrong
This is an extension study with a moderate number of participants. The lenses may not slow myopia significantly for all children, and long-term effects beyond 12 months are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 175 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

8 to 16 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Previously a successfully completed participant in the CATHAY study (NCT05562622) 2. Agree to wear the assigned spectacles constantly except for sleeping, swimming, or other activities in which spectacle wear would be dangerous or otherwise not possible (minimum of 10 hours per day) 3. Willingness to participate in the trial for 12 months without contact lens wear or any other myopia management intervention 4. The subject's parent(s) or legal guardian(s) must read, understand and sign the Statement of Informed Consent and receive a fully executed copy of the form Exclusion Criteria: 1\. Known allergy to proparacaine, tetracaine, or tropicamide or cyclopentolate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Juvenile myopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Juvenile myopia Myopia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aier Eye Hospital

    RECRUITING

    Changsha, China

  • Fudan University EENT

    RECRUITING

    Shanghai, China

  • Tianjin Eye Hospital

    RECRUITING

    Tianjin, China

  • West China Hospital

    RECRUITING

    Chengdu, China

  • Zhongshan Ophthalmic Center

    NOT_YET_RECRUITING

    Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.